Pharming Group N.V. (PHARM.AS)
EUR 0.71
(-4.05%)
EUR 0.71
(-4.05%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 220.1 Million EUR | 2.84% |
| 2022 | 188.06 Million USD | 10.84% |
| 2021 | 169.67 Million EUR | -16.44% |
| 2020 | 203.05 Million EUR | 22.76% |
| 2019 | 165.41 Million EUR | 28.02% |
| 2018 | 129.2 Million EUR | 39.55% |
| 2017 | 92.58 Million EUR | 686.73% |
| 2016 | 11.76 Million EUR | 78.57% |
| 2015 | 6.59 Million EUR | -69.48% |
| 2014 | 21.59 Million EUR | 172.83% |
| 2013 | 7.91 Million EUR | -5.69% |
| 2012 | 8.39 Million EUR | 1319.46% |
| 2011 | -688.22 Thousand EUR | -207.36% |
| 2010 | 641.04 Thousand EUR | -59.18% |
| 2009 | 1.57 Million EUR | 69.88% |
| 2008 | 924.35 Thousand EUR | 102.57% |
| 2007 | -35.89 Million EUR | -18602.9% |
| 2006 | 194.01 Thousand EUR | 103.41% |
| 2005 | -5.69 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 47.2 Million USD | -29.81% |
| 2024 Q2 | 66.11 Million EUR | 40.24% |
| 2024 Q3 | 68.03 Million USD | 3.31% |
| 2023 Q3 | 58.36 Million USD | 18.7% |
| 2023 Q2 | 49.17 Million USD | 27.83% |
| 2023 Q4 | 74.09 Million USD | 26.96% |
| 2023 FY | 193.4 Million EUR | 2.84% |
| 2023 Q1 | 38.46 Million USD | -20.44% |
| 2022 Q4 | 48.34 Million USD | -6.77% |
| 2022 FY | 188.06 Million USD | 10.84% |
| 2022 Q1 | 41.74 Million USD | 2.16% |
| 2022 Q2 | 46.11 Million USD | 10.49% |
| 2022 Q3 | 51.85 Million USD | 12.44% |
| 2021 Q1 | 37.55 Million EUR | -39.57% |
| 2021 Q3 | 43.79 Million EUR | -2.85% |
| 2021 Q4 | 40.85 Million EUR | -6.71% |
| 2021 FY | 169.67 Million EUR | -16.44% |
| 2021 Q2 | 45.07 Million EUR | 20.04% |
| 2020 Q4 | 62.14 Million EUR | 18.69% |
| 2020 Q2 | 40.12 Million EUR | -17.13% |
| 2020 Q3 | 52.35 Million EUR | 30.48% |
| 2020 Q1 | 48.42 Million EUR | 0.35% |
| 2020 FY | 203.05 Million EUR | 22.76% |
| 2019 Q4 | 48.25 Million EUR | 17.69% |
| 2019 FY | 165.41 Million EUR | 28.02% |
| 2019 Q1 | 33.46 Million EUR | 0.17% |
| 2019 Q2 | 42.68 Million EUR | 27.53% |
| 2019 Q3 | 41 Million EUR | -3.94% |
| 2018 FY | 129.2 Million EUR | 39.55% |
| 2018 Q3 | 38 Million EUR | 37.54% |
| 2018 Q2 | 27.63 Million EUR | -8.38% |
| 2018 Q1 | 30.15 Million EUR | -14.51% |
| 2018 Q4 | 33.41 Million EUR | -12.07% |
| 2017 FY | 92.58 Million EUR | 686.73% |
| 2017 Q2 | 16.16 Million EUR | 9.91% |
| 2017 Q3 | 26.43 Million EUR | 63.54% |
| 2017 Q4 | 35.27 Million EUR | 33.44% |
| 2017 Q1 | 14.7 Million EUR | 160.58% |
| 2016 FY | 11.76 Million EUR | 78.57% |
| 2016 Q4 | 5.64 Million EUR | 126.95% |
| 2016 Q3 | 2.48 Million EUR | 32.8% |
| 2016 Q2 | 1.87 Million EUR | 6.13% |
| 2016 Q1 | 1.76 Million EUR | 41.91% |
| 2015 Q2 | 2.39 Million EUR | 183.94% |
| 2015 Q1 | 842.51 Thousand EUR | -95.81% |
| 2015 FY | 6.59 Million EUR | -69.48% |
| 2015 Q4 | 1.24 Million EUR | -41.13% |
| 2015 Q3 | 2.11 Million EUR | -11.7% |
| 2014 Q2 | 730.39 Thousand EUR | 162.91% |
| 2014 Q3 | 489.09 Thousand EUR | -33.04% |
| 2014 FY | 21.59 Million EUR | 172.83% |
| 2014 Q1 | 277.81 Thousand EUR | -35.19% |
| 2014 Q4 | 20.09 Million EUR | 4009.18% |
| 2013 Q3 | 1.1 Million EUR | -80.82% |
| 2013 Q4 | 428.68 Thousand EUR | -61.21% |
| 2013 FY | 7.91 Million EUR | -5.69% |
| 2013 Q1 | 619.81 Thousand EUR | -93.56% |
| 2013 Q2 | 5.76 Million EUR | 829.57% |
| 2012 Q3 | 367.55 Thousand EUR | 116.36% |
| 2012 FY | 8.39 Million EUR | 1319.46% |
| 2012 Q4 | 9.62 Million EUR | 2519.08% |
| 2012 Q1 | 645.65 Thousand EUR | 139.36% |
| 2012 Q2 | -2.24 Million EUR | -448.04% |
| 2011 Q4 | -1.64 Million EUR | -357.13% |
| 2011 Q3 | 637.93 Thousand EUR | 253.42% |
| 2011 Q2 | -415.8 Thousand EUR | -156.96% |
| 2011 FY | -688.22 Thousand EUR | -207.36% |
| 2011 Q1 | 729.95 Thousand EUR | 583.38% |
| 2010 FY | 641.04 Thousand EUR | -59.18% |
| 2010 Q4 | -151.01 Thousand EUR | -141.81% |
| 2010 Q2 | 215.59 Thousand EUR | -22.42% |
| 2010 Q1 | 277.89 Thousand EUR | -64.94% |
| 2010 Q3 | 361.14 Thousand EUR | 67.51% |
| 2009 Q3 | 267.97 Thousand EUR | -23.49% |
| 2009 FY | 1.57 Million EUR | 69.88% |
| 2009 Q4 | 792.72 Thousand EUR | 195.82% |
| 2009 Q2 | 350.26 Thousand EUR | 153.86% |
| 2009 Q1 | 137.97 Thousand EUR | 0.0% |
| 2008 FY | 924.35 Thousand EUR | 102.57% |
| 2007 FY | -35.89 Million EUR | -18602.9% |
| 2006 FY | 194.01 Thousand EUR | 103.41% |
| 2005 FY | -5.69 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -35515.534% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -5523.505% |
| Adocia SA | 1.38 Million EUR | -15791.986% |
| Aelis Farma SA | 12.35 Million EUR | -1681.065% |
| Biophytis S.A. | -803 Thousand EUR | 27510.212% |
| Advicenne S.A. | 1.42 Million EUR | -15335.063% |
| genOway Société anonyme | 20.1 Million EUR | -995.024% |
| IntegraGen SA | 5.01 Million EUR | -4286.045% |
| Medesis Pharma S.A. | -2.66 Million EUR | 8359.781% |
| Neovacs S.A. | 29.31 Thousand EUR | -750749.423% |
| NFL Biosciences SA | -56.06 Thousand EUR | 392694.178% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -10123.525% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 15608.047% |
| Sensorion SA | 3.78 Million EUR | -5710.771% |
| Theranexus Société Anonyme | -4.63 Million EUR | 4844.96% |
| TME Pharma N.V. | -127 Thousand EUR | 173410.236% |
| Valbiotis SA | 2.66 Million EUR | -8149.775% |
| TheraVet SA | -530.79 Thousand EUR | 41566.778% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -17272.06% |
| argenx SE | 925.49 Million EUR | 76.218% |
| BioSenic S.A. | 543 Thousand EUR | -40434.807% |
| Celyad Oncology SA | 33 Thousand EUR | -666881.818% |
| DBV Technologies S.A. | 4.15 Million EUR | -5191.481% |
| Galapagos NV | 203.73 Million EUR | -8.034% |
| Genfit S.A. | 28.22 Million EUR | -679.847% |
| GeNeuro SA | -293.8 Thousand EUR | 75016.27% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | -10938.315% |
| Innate Pharma S.A. | -4.12 Million EUR | 5441.034% |
| Inventiva S.A. | 17.5 Million EUR | -1157.737% |
| MaaT Pharma SA | 1.65 Million EUR | -13199.335% |
| MedinCell S.A. | 9.28 Million EUR | -2269.767% |
| Nanobiotix S.A. | 36.2 Million EUR | -507.888% |
| Onward Medical N.V. | -14.81 Million EUR | 1585.383% |
| Oryzon Genomics S.A. | 13.94 Million EUR | -1478.042% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -9783.431% |
| Oxurion NV | 104 Thousand EUR | -211538.462% |
| Poxel S.A. | 1000.00 EUR | -22010300.0% |
| GenSight Biologics S.A. | 3 Million EUR | -7236.8% |
| Transgene SA | -28.4 Million EUR | 874.905% |
| Financière de Tubize SA | -2.02 Million EUR | 10944.779% |
| UCB SA | 3.34 Billion EUR | 93.414% |
| Valneva SE | 52.83 Million EUR | -316.572% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 7211.599% |